Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells

• Published in: BMC cancer Vol. 12; no. 1; p. 86
• Main Authors: Blaser, Benjamin, Waselle, Laurent, Dormond-Meuwly, Anne, Dufour, Marc, Roulin, Didier, Demartines, Nicolas, Dormond, Olivier
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.03.2012; BioMed Central; BMC
• Subjects: Animals; Antibiotics, Antineoplastic - pharmacology; Blotting, Western; Cancer cells; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Colon cancer; Colonic Neoplasms - drug therapy; Colonic Neoplasms - pathology; Development and progression; Female; Gene expression; Genetic aspects; Humans; Imidazoles - pharmacology; Immunohistochemistry; Indoles - pharmacology; Male; Mice; mTOR; NVP-BEZ235; Physiological aspects; PP242; Proliferation; Protein Kinase Inhibitors - pharmacology; Purines - pharmacology; Quinolines - pharmacology; Rapamycin; Sirolimus - pharmacology; TOR Serine-Threonine Kinases - antagonists & inhibitors; Xenograft; Xenograft Model Antitumor Assays; Switzerland

The mammalian target of rapamycin (mTOR) is frequently activated in colon cancers due to mutations in the phosphatidylinositol 3-kinase (PI3K) pathway. Targeting mTOR with allosteric inhibitors of mTOR such as rapamycin reduces colon cancer progression in several experimental models. Recently, a new...